

Young patient with progressive low-grade glioma

Clinical challenges in neuro-oncology Patient cases (Tumour board) Friday, 18 December 2015 - 14:30-16:00

Danny TM Chan


CUHK Otto Wong Brain Tumour Centre


The Chinese University of Hong Kong


Disclosure


• Nil

F/35 Seizure












How to treat?




Day 1 MRI



Oligoastrocytoma (Grade II)



IDH1-R132H: positive



p53: positive 1p/19q: non-codeleted


Oligoastrocytoma (Grade II)

- IDH-1 mutated
- 1p19q non-deleted
- p53+
- EGFR -


What will you do?


Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

The Cancer Genome Atlas Research Network*





1 year post-Surgery + Radiation







2nd year







3rd year







Post-Op






Secondary GBM









IDH1-R132H: positive

p53: positive




1p/19q: non-codeleted



MGMT: Methylated


Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

The Cancer Genome Atlas Research Network*




Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

The Cancer Genome Atlas Research Network*



ORIGINAL ARTICLE

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors



Summary

 Molecular classification of low grade glioma is up-coming

Improvement in diagnostic accuracy and prognostication

Implications in future therapeutic trials